STOCK TITAN

Accuray Incorp SEC Filings

ARAY Nasdaq

Welcome to our dedicated page for Accuray Incorp SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Accuray’s radiation oncology business is packed with regulatory nuance—each 10-K page covers FDA clearances, global supply chains, and service-contract margins. Finding R&D spend or tracking when executives trade shares should not require hours with spreadsheets. That’s why our SEC filings hub brings Accuray insider trading Form 4 transactions and every other disclosure into one streamlined view.

Stock Titan’s AI reads the fine print for you. Open an Accuray quarterly earnings report 10-Q filing and our algorithms instantly surface backlog changes, CyberKnife unit shipments, and reimbursement commentary. Get Accuray Form 4 insider transactions real-time alerts, side-by-side with revenue trend graphs. Whether you’re understanding Accuray SEC documents with AI for due diligence or need an Accuray annual report 10-K simplified, we translate technical jargon into clear business drivers.

Every filing type is here and searchable: 8-Ks for product-recall updates—see “Accuray 8-K material events explained”—DEF 14A for Accuray proxy statement executive compensation, and of course Form 4 for Accuray executive stock transactions Form 4. Use our AI-powered summaries to compare quarter-over-quarter margin shifts, monitor clinical-trial timelines, and flag warranty reserve changes. With comprehensive coverage, real-time EDGAR pulls, and plain-English insights, you’ll move from document download to actionable perspective in minutes while enjoying Accuray SEC filings explained simply and fast Accuray earnings report filing analysis.

Filing
Rhea-AI Summary

Aevum Pension Fund reports beneficial ownership of 5,473,256 shares of Accuray Inc. common stock, representing 4.86% of the outstanding class. The filing states the shares are held by a pension fund organized in Switzerland and that Aevum has sole voting and dispositive power over the reported shares. The statement certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Accuray Incorporated requests stockholder approval of director elections and a new 2026 Equity Incentive Plan while describing fiscal 2025 compensation outcomes and governance practices. The company reported fiscal 2025 revenue of $459 million (87% of the bonus-plan target), orders net of cancellations of $288 million (97% of target), and adjusted EBITDA of $28.8 million (65% of target), and the Compensation Committee determined not to pay cash incentive awards for fiscal 2025.

The proxy lists three Class I director nominees and Board recommendations to vote FOR the nominees, the 2026 Plan, and the advisory approval of named executive officer compensation. Key equity metrics disclosed include three-year equity grants totaling ~15.06 million shares (FY2023–FY2025), an average three-year burn rate of 3.89%, an overhang of 11% at fiscal year-end, and 4,815,031 shares available for issuance under the 2016 Plan as of June 30, 2025 (increased ~295,000 by terminations).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
proxy
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Anne Bryce Le Grand, a director of Accuray Incorporated (ARAY), reported receipt of 78,947 restricted stock units (RSUs) on 08/29/2025. Each RSU represents a contingent right to one share of the issuer's common stock and the award vests 100% on 08/29/2026, resulting in 78,947 shares beneficially owned following the transaction. The filing was signed by Jesse Chew as Power of Attorney for Anne Bryce Le Grand on 09/03/2025. No cash price was paid for the RSUs as reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Accuray Inc. (ARAY) has received an amended Schedule 13G filing (Amendment No. 5) from Neuberger Berman Group LLC and Neuberger Berman Investment Advisers LLC. As of 07/31/2025 the Neuberger entities beneficially own 5,242,373 common shares, equal to 4.65 % of Accuray’s outstanding stock. The institutions report shared voting power over 3,991,789 shares and shared dispositive power over the full 5,242,373 shares; they hold no sole voting or dispositive authority. Because the position now falls below the 5 % threshold, Item 5 (“ownership of 5 % or less”) is checked. The filing is made under Rule 13d-1(b), classifying the filers as a parent holding company (HC) and an investment adviser (IA). The signatory, Managing Director Brad Cetron, certifies that the shares were acquired in the ordinary course of business and not to influence control of Accuray.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
registration
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Accuray Incorp (ARAY)?

The current stock price of Accuray Incorp (ARAY) is $1.61 as of October 21, 2025.

What is the market cap of Accuray Incorp (ARAY)?

The market cap of Accuray Incorp (ARAY) is approximately 190.5M.
Accuray Incorp

Nasdaq:ARAY

ARAY Rankings

ARAY Stock Data

190.50M
110.03M
2.06%
71.26%
1.97%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MADISON